Serum Institute Seeks Covovax Vaccine Approval For 12-17 Year Olds

Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.

Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.

The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.

Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.

Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.

Currently, only those in the 15-17 year age group are being inoculated in India.